Queensland’s government has proposed increasing the maximum penalty for drivers with a drug present in blood or saliva and doubling penalties for combined drink and drug driving. The legislation is being reviewed by a parliamentary committee before debate.

ABC News reported on July 27 that the Alcohol and Drug Foundation warned the proposal could affect people who use prescribed medical cannabis. Read the source report.

A prescription does not necessarily create a defense to a roadside THC offense in Queensland. Do not rely on feeling normal, a product label, or a fixed number of hours as proof that driving is lawful or safe.

Ask the prescriber how route, dose, timing, titration, other sedating medicines, sleep loss, alcohol, and medical conditions may affect driving. Make a transportation plan before starting or changing a THC-containing product.

Driving counseling should separate clinical impairment from legal detection rules. Document the product, cannabinoid content, route, dose, timing, concurrent sedatives, adverse effects, and the patient’s transportation needs.

Avoid presenting a universal waiting period as a legal guarantee. Product pharmacokinetics, individual response, repeated use, and local law can differ.

Australian jurisdictions are taking different approaches to prescribed THC and driving. The policy problem is how to protect road users while avoiding the assumption that any detectable THC level proves current impairment.

Queensland’s debate is distinct from recent changes elsewhere because this bill focuses on stronger penalties and retains a zero-tolerance approach while a committee considers objections.

The report does not show that prescribed cannabis users are safe to drive whenever they feel unimpaired. It also does not show that every positive saliva result corresponds to the same degree of crash risk.

The bill is not yet law. The committee may recommend changes, and the final text or implementation could differ.

THC can affect attention, reaction time, coordination, judgment, and lane control. Risk can be greater during dose changes, with higher doses, after inhalation, with alcohol or sedating medicines, and when a patient is sleep deprived or unwell.

CBD-dominant and THC-containing products are not interchangeable for this discussion. Product composition, labeling accuracy, route, and actual exposure matter.

The government cites road trauma and THC findings in fatalities, but the news report does not provide case-level data capable of separating impairment, recent use, other drugs, alcohol, or crash circumstances.

Advocacy submissions also have a policy objective. Claims about unfairness, deterrence, and safety should be tested against transparent enforcement, toxicology, crash, and patient data.

The central policy question is not whether impaired driving should be permitted. It is whether the law can distinguish drivers who present a current safety risk from patients with residual detectable THC after lawful use.

A credible system would need clear rules, validated testing, proportional penalties, patient education, clinician guidance, and public reporting on safety and enforcement outcomes.

Driving policy must address both genuine impairment and the limits of available roadside tests.

Medical cannabis counseling should include legal and functional risks, not only symptom response and adverse effects.

This debate becomes less confusing when we separate three questions: Was the product prescribed, is THC detectable, and is the person impaired? Those questions can overlap, but they are not interchangeable.

Patients deserve clear warnings before treatment, not after a roadside test. Clinicians should discuss transportation early, especially during titration or when THC is combined with alcohol, sleep medicines, opioids, antihistamines, or other sedating agents.

Four distinctions that matter